๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Ras signaling in prostate cancer progression

โœ Scribed by Michael J. Weber; Daniel Gioeli


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
141 KB
Volume
91
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

When prostate cancer is first detected it generally is dependent on the presence of androgens for growth, and responds to androgen ablation therapies. However, the disease often recurs in a disseminated and apparently androgen independent (AI) form, and in this state is almost invariably fatal. Considerable evidence indicates that the Androgen receptor (AR) continues to be required even in androgen independent (AI) disease. Thus, a key to understanding hormone independent prostate cancer is to determine the mechanism(s) by which the AR can function even in the absence of physiologic levels of androgen. In this article, we argue that growth factors and receptors that utilize Ras family members drive prostate cancer progression to a state of androgen hypersensitivity; and that postโ€translational modifications (e.g., phosphorylations) of transcriptional cofactors might be responsible for modulating the function of the AR so that it is active even at low concentrations of androgen. ยฉ 2003 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Interaction of IGF signaling and the and
โœ Jennifer D. Wu; Kathy Haugk; Libby Woodke; Peter Nelson; Ilsa Coleman; Stephen R ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 352 KB ๐Ÿ‘ 2 views

## Abstract The insulinโ€like growth factor type I receptor (IGFโ€IR) has been suggested to play an important role in prostate cancer progression and possibly in the progression to androgenโ€independent (AI) disease. The term AI may not be entirely correct, in that recent data suggest that expression

Genetic pattern of prostate cancer progr
โœ Tomo Saric; Zoran Brkanac; Dean A. Troyer; Susan S. Padalecki; Michael Sarosdy; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 71 KB ๐Ÿ‘ 2 views

Genetic alterations in primary prostate cancer (CaP) have been extensively studied, yet little is known about the genetic mechanisms underlying progression of primary CaP to metastatic prostate cancer. As a result, it is not possible to distinguish clinically indolent localized disease from potentia

Predictors of cancer progression in T1a
โœ Liang Cheng; Erik J. Bergstralh; Beth G. Scherer; Roxann M. Neumann; Michael L. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 82 KB ๐Ÿ‘ 2 views

## BACKGROUND. The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk

Functional evidence implicating S100P in
โœ Gargi D. Basu; David O. Azorsa; Jeffrey A. Kiefer; Angela M. Rojas; Sukru Tuzmen ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 425 KB

## Abstract S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. We have previously shown how elevated S100P levels in prostate cancer strongly correlate with progression to metastatic disease. In our study,

Progress in active specific immunotherap
โœ Benjamin A. Tjoa; Gerald P. Murphy ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 2 views

Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system